Oramed Pharmaceuticals Stock Performance
| ORMP Stock | USD 3.52 0.16 4.35% |
On a scale of 0 to 100, Oramed Pharmaceuticals holds a performance score of 19. The company holds a Beta of 2.08, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Oramed Pharmaceuticals will likely underperform. Please check Oramed Pharmaceuticals' maximum drawdown, and the relationship between the information ratio and expected short fall , to make a quick decision on whether Oramed Pharmaceuticals' historical price patterns will revert.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Oramed Pharmaceuticals are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. Even with relatively unsteady primary indicators, Oramed Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.27) | Five Day Return 7.29 | Year To Date Return 26.46 | Ten Year Return (42.86) | All Time Return (69.33) |
Forward Dividend Yield 0.0679 | Payout Ratio | Last Split Factor 1:12 | Forward Dividend Rate 0.25 | Dividend Date 2026-01-26 |
1 | Disposition of 3000 shares by Mayer Arie of Oramed Pharmaceuticals at 25.6 subject to Rule 16b-3 | 11/07/2025 |
2 | Will Oramed Pharmaceuticals Inc. stock continue upward momentum - Trade Risk Assessment Verified Swing Trading Watchlists - newser.com | 11/11/2025 |
3 | Oramed Q3 Earnings Snapshot | 11/13/2025 |
4 | Oramed Reports Fiscal Third Quarter 2025 Financial Results | 11/17/2025 |
5 | There Are Some Holes In Oramed Pharmaceuticals Solid Earnings Release | 11/21/2025 |
6 | How Oramed Pharmaceuticals Inc. stock correlates with oil markets - Weekly Profit Summary Long Hold Capital Preservation Tips - Newser | 12/01/2025 |
7 | Acquisition by Avraham Gabay of 19000 shares of Oramed Pharmaceuticals subject to Rule 16b-3 | 12/31/2025 |
8 | Oramed Receives 18 Million Payment from Scilex Holdings, Bringing Current Returns to 118 Million Board Approves Dividend Payments | 01/07/2026 |
9 | Oramed Pharmaceuticals Inc. - marketscreener.com | 01/15/2026 |
| Begin Period Cash Flow | 9.1 M | |
| Total Cashflows From Investing Activities | 105.8 M |
Oramed Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 213.00 in Oramed Pharmaceuticals on October 22, 2025 and sell it today you would earn a total of 139.00 from holding Oramed Pharmaceuticals or generate 65.26% return on investment over 90 days. Oramed Pharmaceuticals is currently generating 0.8713% in daily expected returns and assumes 3.4731% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than Oramed, and 83% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Oramed Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oramed Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Oramed Pharmaceuticals, and traders can use it to determine the average amount a Oramed Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2509
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ORMP | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Oramed Pharmaceuticals is performing at about 19% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Oramed Pharmaceuticals by adding it to a well-diversified portfolio.
Oramed Pharmaceuticals Fundamentals Growth
Oramed Stock prices reflect investors' perceptions of the future prospects and financial health of Oramed Pharmaceuticals, and Oramed Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oramed Stock performance.
| Return On Equity | 0.24 | ||||
| Return On Asset | -0.0422 | ||||
| Profit Margin | 21.93 % | ||||
| Operating Margin | (6.51) % | ||||
| Current Valuation | 12.65 M | ||||
| Shares Outstanding | 39.8 M | ||||
| Price To Earning | (11.22) X | ||||
| Price To Book | 0.72 X | ||||
| Price To Sales | 73.32 X | ||||
| Gross Profit | 13 K | ||||
| EBITDA | (14.87 M) | ||||
| Net Income | (19.06 M) | ||||
| Cash And Equivalents | 133.91 M | ||||
| Cash Per Share | 3.45 X | ||||
| Total Debt | 372 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 21.01 X | ||||
| Book Value Per Share | 4.98 X | ||||
| Cash Flow From Operations | (8.41 M) | ||||
| Earnings Per Share | 1.00 X | ||||
| Market Capitalization | 146.64 M | ||||
| Total Asset | 155.28 M | ||||
| Retained Earnings | (176.62 M) | ||||
| Working Capital | 137.54 M | ||||
| Current Asset | 31 M | ||||
| Current Liabilities | 4 M | ||||
About Oramed Pharmaceuticals Performance
Assessing Oramed Pharmaceuticals' fundamental ratios provides investors with valuable insights into Oramed Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Oramed Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.11) | (0.12) | |
| Return On Capital Employed | (0.08) | (0.08) | |
| Return On Assets | (0.11) | (0.12) | |
| Return On Equity | (0.13) | (0.12) |
Things to note about Oramed Pharmaceuticals performance evaluation
Checking the ongoing alerts about Oramed Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Oramed Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oramed Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (19.06 M) with profit before overhead, payroll, taxes, and interest of 13 K. | |
| Oramed Pharmaceuticals currently holds about 133.91 M in cash with (8.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.45. | |
| Oramed Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 15.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Oramed Pharmaceuticals Inc. - marketscreener.com |
- Analyzing Oramed Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oramed Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Oramed Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oramed Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oramed Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Oramed Pharmaceuticals' stock. These opinions can provide insight into Oramed Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Oramed Stock Analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.